Global Necrotising Enterocolitis Market Size By Type (Stage I, Stage II), By Application (Hospitals & Clinics, Ambulatory Surgical Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Necrotising Enterocolitis (NEC) Market was valued at USD 540 million in 2023 and is projected to surpass USD 950 million by 2031, growing at a CAGR of 7.2% during the forecast period from 2023 to 2031. The rising prevalence of preterm births, increasing awareness regarding neonatal health, and advancements in diagnostic techniques and treatment options are key drivers of the market. NEC is a severe gastrointestinal disease that primarily affects premature infants, leading to inflammation, infection, and in severe cases, intestinal necrosis. The demand for effective therapeutics, probiotics, and preventive measures is fueling market expansion.

Drivers:

1. Increasing Premature Birth Rates:

Prematurity is the leading risk factor for necrotising enterocolitis. According to the World Health Organization (WHO), an estimated 15 million babies are born preterm each year, and this number is expected to rise. The increasing rate of preterm births, particularly in developing nations, is driving the need for advanced diagnostics and treatment options for NEC.

2. Growing Investments in Neonatal Healthcare:

Governments and healthcare organizations are investing heavily in neonatal intensive care units (NICUs) and research on neonatal diseases. This has led to the development of new therapeutic approaches, including probiotics, antimicrobial therapies, and advanced surgical procedures to manage severe NEC cases.

3. Advancements in Diagnostic and Treatment Approaches:

Innovations in biomarker-based detection, non-invasive imaging technologies, and probiotic-based preventive therapies are revolutionizing NEC management. Early detection techniques and personalized medicine approaches are reducing NEC-related mortality and long-term complications.

Restraints:

1. High Treatment Costs:

The cost of treating NEC, especially in severe cases requiring surgery, can be exorbitant. Surgical interventions, prolonged NICU stays, and advanced antimicrobial treatments impose a significant financial burden on healthcare systems and families.

2. Limited Availability of Effective Therapies:

Despite advances in NEC management, there is no universally effective therapy that completely prevents or treats the condition. The lack of approved drugs and the variability in response to probiotics present challenges to healthcare providers.

3. Ethical and Regulatory Challenges in Neonatal Research:

Clinical trials involving neonates face ethical and regulatory hurdles, which slow down the approval process for new drugs and treatments. The limited population available for trials also restricts the pace of research and innovation.

Opportunity:

1. Development of Novel Therapies:

Pharmaceutical and biotech companies are investing in the development of probiotic formulations, stem cell-based therapies, and anti-inflammatory agents for NEC prevention and treatment. The approval of innovative drugs can create new market opportunities.

2. Expansion of Neonatal Care in Emerging Markets:

Asia-Pacific and Latin America are witnessing a surge in neonatal healthcare investments. The expansion of NICUs, increased awareness, and improved healthcare infrastructure are expected to drive market growth in these regions.

3. Increasing Research on Gut Microbiome and NEC:

The gut microbiome plays a crucial role in NEC pathogenesis. Research into microbiota-targeted therapies, fecal microbiota transplants (FMTs), and next-generation probiotics is opening new avenues for NEC management.

Market by Treatment Insights:

1. Probiotics-Based Treatment

The probiotic therapy segment is witnessing significant growth, as probiotics such as Bifidobacterium and Lactobacillus have shown promising results in reducing NEC incidence. This segment is expected to grow due to rising clinical evidence and approvals from regulatory authorities.

2. Surgical Intervention

For severe cases of NEC leading to intestinal necrosis and perforation, surgical intervention is necessary. Although surgery is the last resort, it accounted for a significant market share in 2023 due to rising preterm birth complications.

3. Antibiotic Therapy

Broad-spectrum antibiotics are commonly used in NEC management. The increasing use of targeted antimicrobial therapies and combination antibiotic regimens is supporting market growth.

Market by End-Use Insights:

1. Hospitals and Neonatal Intensive Care Units (NICUs)

Hospitals and NICUs hold the largest market share, as NEC primarily affects newborns in intensive care settings. The expansion of NICUs in developing nations is expected to further drive growth in this segment.

2. Research Institutes and Biopharmaceutical Companies

Pharmaceutical companies and research institutes are actively investing in NEC-related drug development. Increasing research in neonatal infections and gut microbiota is boosting demand in this segment.

Market by Regional Insights:

1. North America

North America held the largest market share in 2023, driven by high healthcare spending, advanced neonatal care facilities, and strong research infrastructure. The U.S. leads the market due to a high incidence of preterm births and government funding for neonatal health.

2. Europe

Europe follows closely, with countries like Germany, France, and the UK investing in advanced neonatal treatments and research on gut microbiota and NEC therapies.

3. Asia-Pacific

Asia-Pacific is expected to witness the highest growth rate, driven by rising healthcare investments, increasing preterm birth rates, and improved neonatal care infrastructure in China and India.

4. Latin America and Middle East & Africa

These regions are emerging markets, with growing awareness and increasing investments in neonatal healthcare. However, limited healthcare accessibility and lack of awareness still pose challenges.

Competitive Scenario:

Key players in the Global Necrotising Enterocolitis Market include:

Abbott Laboratories

Mead Johnson Nutrition

Baxter International Inc.

BioGaia AB

Reckitt Benckiser Group PLC

Prolacta Bioscience

Aptalis Pharma Inc.

Pediatrix Medical Group

These companies are focusing on new drug formulations, probiotic-based therapies, and collaborations with healthcare institutions to strengthen their market position.

Scope of Work – Global Necrotising Enterocolitis Market

Report Metric Details

Market Size (2023) USD 540 million

Projected Market Size (2031) USD 950 million

CAGR (2023-2031) 7.2%

Key Segments by Treatment Type Probiotics-Based Treatment, Surgical Intervention, Antibiotic Therapy

Key Segments by End-Use Hospitals & NICUs, Research Institutes & Biopharmaceutical Companies

Leading Region North America

Key Players Abbott Laboratories, Mead Johnson Nutrition, Baxter International, BioGaia AB, Reckitt Benckiser, Prolacta Bioscience

Growth Drivers Rising preterm birth rates, growing neonatal healthcare investments, advancements in NEC diagnostics and treatments

Opportunities Development of novel therapies, research on gut microbiota, expansion of neonatal care in emerging markets

Key Market Developments:

2023: Abbott Laboratories launched a new probiotic-enriched infant formula designed to reduce the risk of NEC in preterm infants.

2024: Prolacta Bioscience introduced next-generation human milk-based fortifiers to enhance neonatal nutrition and NEC prevention.

2025: Baxter International announced a collaboration with neonatal research centers to develop targeted antimicrobial therapies for NEC treatment.

FAQs:

1. What is the current market size of the Global Necrotising Enterocolitis Market?

The market was valued at USD 540 million in 2023.

2. What is the major growth driver of the Global Necrotising Enterocolitis Market?

The major driver is the increasing rate of preterm births, leading to a higher incidence of NEC.

3. Which is the largest region during the forecast period in the Global Necrotising Enterocolitis Market?

North America holds the largest market share due to advanced neonatal care infrastructure.

4. Which segment accounted for the largest market share in the Global Necrotising Enterocolitis Market?

The Hospitals & NICUs segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Necrotising Enterocolitis Market?

Key players include Abbott Laboratories, Mead Johnson Nutrition, Baxter International, BioGaia AB, and Prolacta Bioscience.